Log In
BCIQ
Print this Print this
 

Relonsiv (NU100) (formerly BaroFeron)

  Manage Alerts
Collapse Summary General Information
Company BaroFold Inc.
DescriptionRecombinant interferon (IFN) beta-1b
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase III
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS); Treat relapsing-remitting multiple sclerosis (RRMS)
Regulatory Designation
PartnerAvecia Ltd.;
Nuron Biotech Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
Get a free BioCentury trial today